Introduction {#s1}
============

During S-phase of the cell cycle, production of the core histone proteins (H2A, H2B, H3, and H4) is coordinated with DNA replication ([@bib25]; [@bib17]). Metazoan mRNAs encoding for the 'replication-dependent' (RD) core histones lack the normal polyA tail formed by 3\' end hydrolysis of pre-mRNA followed by polyadenylation ([@bib45]). Instead, they undergo endonucleolytic cleavage at the 3ʹ side of an RNA hairpin (stem loop) producing mRNA with a 3´stem loop (SL), which is exported from the nucleus for use in translation ([@bib39]; [@bib40]). By contrast, the pre-mRNA of replication-independent histone variants are normally polyadenylated and constitutively expressed during the cell cycle ([@bib38]; [@bib61]).

A single endonuclease, cleavage and polyadenylation specificity factor 73 (CPSF73), is proposed to be responsible for the hydrolysis of both RD histone pre-mRNA (SL) and normal protein-coding pre-mRNA (polyA) ([@bib12]; [@bib36]; [@bib31]; [@bib58]; [@bib14]). Although maturation of both classes of RNAs requires a hydrolytic reaction, different macromolecular complexes are recruited to the different pre-mRNA classes (SL or polyA) ([@bib31]; [@bib58]). Specific factors involved in RD histone pre-mRNA maturation are the stem loop binding protein (SLBP), the FLICE-associated huge protein (FLASH), and the U7 small nuclear ribonucleoprotein (U7snRNP) that binds to a histone downstream element (HDE) ([@bib12]; [@bib31]; [@bib58]). Defective 3ʹ end processing of RD histone pre-mRNA, caused by depletion of factors including CPSF73, SLBP, Sm-like protein 11 (Lsm11), CstF64 or FLASH, results in the generation of extended transcripts downstream of the HDE sequence ([@bib57]; [@bib49]; [@bib58]). In *Drosophila melanogaster* and humans, misprocessed RD histone pre-mRNA has been observed to undergo polyadenylation involving utilization of a secondary polyadenylation signal sequence located downstream of the HDE ([@bib58]; [@bib49]; [@bib27]). Depletion of factors belonging to the 5ʹ cap-binding complex (CBC) ([@bib23], [@bib41]; [@bib22]), or to the cleavage factor II (CF IIm), which is normally involved in 3ʹ end processing of normal protein-coding pre-mRNA (polyA) ([@bib23]; [@bib10]), also results in extended RD histone pre-mRNA transcripts ([@bib23]). These observations suggest a complex and dynamic relationship between the factors involved in the different stages of the RD histone pre-mRNA transcription process, which may involve participation of factors normally belonging to the polyA mRNA processing machinery.

Important cancer medicines, including histone deacetylase and cyclin-dependent kinase inhibitors, target proteins involved in the S-phase ([@bib42]; [@bib18]). In work aimed at identifying potential new S-phase cancer targets, we considered known and potential roles of MBL-fold proteins involved in nucleic acid hydrolysis ([@bib13]; [@bib44]; [@bib8]). In addition, to the role of CPSF73, and the likely pseudo-enzyme CPSF100, in pre-mRNA processing ([@bib12]; [@bib36]), MBL-fold nucleases are involved in DNA repair (SNM1A-C nucleases) ([@bib64]), snRNA processing (INTS9 and INTS11), and tRNA processing (ELAC 1 and 2) ([@bib54]; [@bib60]). Whilst most of the \~18 human MBL-fold proteins have established functions ([@bib44]), the functions of several are unassigned, including the MBL domain containing protein 1 (MBLAC1). Here, we report evidence that MBLAC1 is a nuclease specific for cleavage of RD histone pre-mRNA. Crystallographic and biochemical studies show that MBLAC1 has an overall MBL fold and di-zinc ion containing active site related to that of CPSF73, but which has distinctive structural features involving active site flanking loops and the absence of the β-CASP domain, which is only present in CPSF73. MBLAC1 depletion from cells leads to the production of unprocessed RD histone pre-mRNA due to inefficient 3ʹ end processing. The consequent depletion of core histone proteins correlates with a cell cycle defect due to a delay in entering/progressing through S-phase.

Results {#s2}
=======

MBLAC1 structure reveals similarity with MBL-fold nucleases {#s2-1}
-----------------------------------------------------------

On the basis of sequence similarity studies MBLAC1 has been assigned as an RNAse Z and glyoxalase II subfamily enzyme ([@bib48]; [@bib53]) ([Figure 1---figure supplement 1A](#fig1s1){ref-type="fig"}). However, we found that recombinant MBLAC1 prepared from *E. coli* has only low, likely non-specific, glyoxalase activity as observed for other hMBL-fold proteins belonging to the same subfamily ([@bib52]). To investigate its function, we solved a crystal structure of MBLAC1 (1.8 Å resolution, space group P1) ([Table 1](#table1){ref-type="table"}). The structure reveals a stereotypical αββα MBL- fold ([@bib7]) with two central mixed β-sheets (I and II), comprised of 8 and 5 strands respectively, surrounded by helices ([Figure 1A](#fig1){ref-type="fig"}). In β-sheet I, β-strands 1, 2, 5--6 and 8--10 are anti-parallel, with β-strands 6--8 being parallel; β-strands 3 and 4 are part of a loop region and are aligned anti-parallel to each other and parallel to β-strands 2 and 5, respectively. In β-sheet II, β-strands 11, 12, 13 and 14 are anti-parallel, and β-strands 14 and 15 are parallel ([Figure 1A](#fig1){ref-type="fig"}). MBLAC1 has four of the five characteristic MBL-metal-binding motifs ([@bib44]), His116, His118 Asp120 and His121 (motif II), His196 (motif III), Asp221 (motif IV) and His263 (motif V) ([Figure 1B](#fig1){ref-type="fig"}) (using BBL numbering) ([@bib20]) with two waters completing metal coordination. In the structure of recombinant MBLAC1 produced in *E. coli*, the active site was refined with two iron ions present ([Figure 1B](#fig1){ref-type="fig"}). However, MBLAC1 produced in HEK293 cells preferentially binds zinc ions ([Figure 1C](#fig1){ref-type="fig"}). Four MBLAC1 molecules (chains A-D) are present in the crystallographic asymmetric unit; analysis of interactions at the crystallographically observed monomer interfaces ([@bib32]) identified interactions between chains A-B and C-D ([Figure 1D](#fig1){ref-type="fig"}) possibly reflecting dimeric MBLAC1 in solution ([Figure 1E and F](#fig1){ref-type="fig"}). The metal containing active site is adjacent to the dimer interface ([Figure 1D](#fig1){ref-type="fig"}), rationalizing reduced dimerization as manifested by metal ligand substitution or metal removal ([Figure 1E--G](#fig1){ref-type="fig"}).
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###### Crystallographic data and refinement statistics PDB ID 4V0H.

  ------------------------------------------------------------
                              Native HSE\
                              (PDB ID: 4V0H)
  --------------------------- --------------------------------
  Data collection             

  Space group                 *P1*

  Cell dimensions             

  *a*, *b*, *c* (Å)           62.95, 67.13, 67.90

  *α, β, γ* (°)               109.31, 105.40, 90.17

  Resolution (Å)              45.96--1.79 (1.84--1.79 Å)^\*^

  *R*~merge~^†^               0.10 (0.81)

  *I/*σ(*I*)                  12.4 (2.6)

  Completeness (%)            95.5 (92.6)

  Redundancy                  6.9 (6.7)

                              

  Refinement                  

  Resolution (Å)              45.95--1.79

  No. reflections             90641

  *R*~work~^‡^/*R*~free~^§^   0.182/0.211

  No. atoms                   

  Protein                     6235

  Ligand/ion                  38

  Water                       514

  *B* factors                 

  Protein                     27.27

  Ligand/ion                  44.40

  Water                       33.94

  R.m.s. deviations           

  Bond lengths (Å)            0.01

  Bond angles (°)             1.37
  ------------------------------------------------------------

^\*^ Values in parentheses are for highest-resolution shell.

^†^Rmerge = ∑*~h~* ∑*~l~* \| I*~hl~* - \< I*~h~* \> \| / ∑*~h~* ∑*~l~* \< I*~h~* \> where I*~hl~* is the *l*th observation of reflection h, and \<I*~h~* \> is the mean intensity of that reflection.

^‡^R*work* = ∑ \|\| F~obs~ \|-\|F~calc~\|\|/\|F~obs~\| x 100.

^§^Rfree is calculated in the same way as R*work* but using a test set containing 5.01% of the data, which were excluded from the refinement calculation.

![MBLAC1 is a dimeric metallo β-lactamase fold protein related in structure to LACTB2.\
(**A**) View from an MBLAC1 crystal structure (PDB ID: 4V0H) showing secondary structure elements and the di-metal containing active site. Helices are in cyan, β-strands in yellow, and metal ions are orange spheres. Dashed line (in gray) indicates unrefined residues (aa 51--66). (**B**) View of metal binding and active site residues with a representative electron density map (3.0 σ mFo-DFc OMIT; cyan mesh) for the sidechains of His116 (Nε2 to M~1~: 2.33 Å), His118 (Nε1 to M~1~: 2.35 Å), Asp120 (Oδ2 to M~2~: 2.9 Å), His121 (Nε2 to M~2~: 2.37 Å), His196 (Nε2 to M~1~: 2.27 Å), Asp221 (Oδ2 to M~1~: 2.14 Å; Oδ2 to M~2~: 2.12 Å), His263 (Nε2 to M~2~: 2.06 Å) and the two water molecules (red spheres) which coordinate (black dashed lines) to the metals (orange spheres). The BBL MBL numbering system is used ([@bib20]) (active site motif numbers in parentheses) ([@bib44]). Numbering as used in our PDB deposited structure is in bold. (**C**) Inductively coupled plasma mass spectrometry (ICP-MS) experiments reveal that in human cells MBLAC1 binds zinc. (**D**) MBLAC1 dimer model calculated by PISA ([@bib32]). A surface representation is shown for protomer A/C. (**E**) Multi-angle laser light scattering (MALS) analyses of *E. coli* produced wt and active site variant MBLAC1, and of HEK293 produced wtMBLAC1. Peak A likely represents a trimer (\~80000 Da); peak B (\~54000 Da) a dimer; and peak C (\~27000 Da) a monomer. wt MBLAC1 is predominantly dimeric, the active site variant is mainly monomeric. The latter observation correlates with loss of activity of active site variant MBLAC1 (main text [Figure 4a](#fig4){ref-type="fig"}), the proposal that the dimer is catalytically active, and the observation that the active site is close to the dimer interface. MALS experiments were carried out at the Biophysical Services of the Biochemistry Dept., Oxford University. (**F**) Non-denaturing PAGE analyses indicates wt MBLAC1 produced in either *E. co*li or HEK293 cells is predominantly dimeric; a higher oligomeric state (tetramer) is also observed for the bacterial produced wt protein. The active site substituted enzyme produced in *E. coli* shows loss of oligomerization. wtMBLAC1 produced in either, *E. coli* or HEK293 cells shows the same oligomerization behavior. (**G**) Non-denaturing electrospray ionization mass spectrometry deconvoluted spectra of recombinant MBLAC1 produced in *E. coli* indicates that MBLAC1 is dimeric, binding two metal ions. Peak A (54880 Da) represents the dimer with two divalent transition metal ions (zinc or iron) bound to each monomer (+224 Da); peaks B and C (27440 and 54880 Da, respectively) correspond to monomer and dimer without bound metal, following metal removal using EDTA. (**H**) Superimposition of the MBLAC1 (cyan; metals in orange) and LACTB2 folds (PDB ID: 4AD9) ([@bib34]) (pink; metals in grey) reveals a high degree of overall similarity (RMSD 2.2 Å over 153 Cα atoms). ](elife-39865-fig1){#fig1}

Comparison of the MBLAC1 structure with those of other MBL-fold proteins reveals that it is indeed part of the RNAse Z/glyoxalase II MBL structural subfamily ([Figure 1H](#fig1){ref-type="fig"}; [Figure 1---figure supplement 1B--C](#fig1s1){ref-type="fig"}). However, although there is low overall sequence similarity (27%), the overall MBLAC1 fold is structurally similar to the human endoribonuclease β-lactamase-like-protein 2 ([@bib34]) (LACTB2), RMSD 2.23 Å over 153 Cα atoms ([@bib33]) ([Figure 1H](#fig1){ref-type="fig"}), an endoribonuclease responsible for mitochondrial mRNA maturation ([@bib34]). Comparison of the MBLAC1 and LACTB2 active sites reveals very similar di-metal ion binding modes and proximate active site residues ([Figure 1---figure supplement 1B](#fig1s1){ref-type="fig"}). Two loops close to the MBLAC1 active site (β3-β4 and β14-α3 loops) are also present in LACTB2 (β1-β2 and β11-α3 loop) ([Figure 1H](#fig1){ref-type="fig"}), suggesting the enzymes have similar substrate recognition/catalytic mechanisms. Studies on the 'true' MBLs involved in β-lactam antibiotic resistance, imply the two active site loops of MBLAC1 are likely mobile and involved in induced fit binding and in substrate recognition ([@bib5]), thus it is possible that the crystallographically observed loop conformations reflect those involved in productive substrate binding/catalysis. Two other regions in the MBLAC1 structure (aa 51--66 and the C-terminal region, aa 239--266) are disordered, implying flexibility and possible involvement in substrate recognition. LACTB2 is reported to have high overall structural similarity with CPSF73 ([@bib34]). However, whilst comparison of the MBL domains of MBLAC1 and CPSF73 reveals similar di-zinc ion binding modes, there are clear differences in their active site flanking loops; only the β3-β4 MBLAC1 active site loop (β1-β2 in LACTB2), is present in CPSF73 (β1-β2 loop), where it is relatively shorter ([Figure 1---figure supplement 1D](#fig1s1){ref-type="fig"}).

Loss of MBLAC1 impairs cell cycle progression {#s2-2}
---------------------------------------------

We sought to gain insight into the biological role of MBLAC1 by its depletion in HeLa cells using siRNA. Flow cytometry reveals that unsynchronised cells depleted for MBLAC1 show a cell cycle defect ([Figure 2A](#fig2){ref-type="fig"}). This is manifested by increased accumulation of cells in G~1~/early S-phase and decreased proportions of cells in G~2~ compared to controls. Furthermore, cells synchronised in early S-phase using a double thymidine block ([@bib24]) and harvested immediately after block release show the expected G~1~/early S phenotype ([Figure 2A](#fig2){ref-type="fig"}). However, 4 hours post-release, control cells progressed normally through the cell cycle, while MBLAC1 depleted cells displayed a strong delay in G~1~/early S-phase. Western blots were then used to investigate the nature of the delay in cell cycle progression by monitoring levels of cyclin D1, a cell cycle protein marker expressed during G~1~ ([@bib9]) ([Figure 2B](#fig2){ref-type="fig"}). Cyclin D1 was hardly detectable in controls, but was strongly upregulated with MBLAC1 depletion ([Figure 2B](#fig2){ref-type="fig"}). These results are consistent with a relatively stronger G~1~ block with MBLAC1 depletion compared to control cells ([Figure 2A--B](#fig2){ref-type="fig"}). Given a possible role for MBLAC1 in cell cycle progression, both unsynchronised and early S-phase synchronised wild-type HeLa cells (using a double thymidine block) were used to investigate the endogenous subcellular distribution of MBLAC1 during S-phase. Western blot analyses reveal the presence of MBLAC1 in both the cytosol and nucleus ([Figure 2C](#fig2){ref-type="fig"}). However, a fraction of MBLAC1 was consistently observed to localise in the nuclear compartment during early S-phase of the cell cycle (and less consistently at later S-phase time points), suggesting a cell-cycle-dependent nuclear function for MBLAC1.

![Loss of MBLAC1 impairs cell cycle progression.\
(**A**) Cell cycle analyses of MBLAC1-depleted cells. Analyses were on unsynchronised cells, or after cell synchronization (using a double thymidine block) as indicated. Flow cytometry profiles were obtained by PI staining. Control siRNA (siLUC) transfected cells were used for reference. (**B**) Western blots evaluating knockdown efficiency of MBLAC1 after siRNA treatment, in unsynchronised and synchronised cells. Cyclin D1 (G~1~ marker) levels were analysed. β-Actin was used as a control. Control siRNA (siLUC) transfected cells were used for reference. (**C**) Western blot analysis showing cellular distribution of endogenous MBLAC1 after subcellular fractionation in unsynchronised (-) and early S-phase synchronised HeLa cells (+) at different time points after release from a double thymidine block. Note the presence of MBLAC1 in the nucleus in early S-phase. α-Tubulin and lamin A/C were used as cytosolic and nuclear markers, respectively.](elife-39865-fig2){#fig2}

Following the observation of nuclear localised MBLAC1 during S-phase and our crystallographic analyses which suggested MBLAC1 as a possible ribonuclease distinct from, but related to, CPSF73, both proteins were depleted in HeLa cells using siRNA to investigate the roles of MBLAC1 in S-phase. Incorporation of 5-bromo-2\'-deoxyuridine (BrdU) into newly synthesised DNA in synchronised cells was monitored by flow cytometry ([Figure 3A](#fig3){ref-type="fig"}, left graph) followed by propidium iodide (PI) staining ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}). The abundance of BrdU positive cells, corresponding to S-phase cells, was strongly reduced in MBLAC1 and CPSF73 knockdowns at early time points (30 min, 1 hr), compared to controls ([Figure 3A](#fig3){ref-type="fig"}, left graph). Subsequent time points displayed a reduced difference, though 6 hr post release a consistent pool of G~1~ cells was still apparent in MBLAC1-depleted cells compared to both control and CPSF73-depleted cells ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}). These results indicate that both MBLAC1 and, as expected, CPSF73 depleted cells are impaired in efficiently entering/progressing in S-phase. Although both depletions displayed a delay 30 min post-release, the defect was more pronounced with MBLAC1 depletion over the full cell cycle, implying a cell-cycle-specific role for MBLAC1 ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}). Western blot analyses indicated that in control samples (siLuc) MBLAC1 levels were increased 6 hr post-release ([Figure 3B](#fig3){ref-type="fig"}) corresponding to mid S-phase (as shown by flow cytometry profiles, [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}). These observations support a specific role for MBLAC1 during S-phase. By contrast, CPSF73 expression levels were relatively constant across the cell cycle (18 hr), consistent with its broad role in pre-mRNA processing ([@bib36]) ([Figure 3B](#fig3){ref-type="fig"}). Although both MBLAC1 and CPSF73-depleted cells progress through the complete cell cycle, levels of cyclins D1 (G~1~ marker) and E (a G~1~/S boundary and S progression marker) were strongly modified compared to controls. As described above, cyclin D1 levels were strongly upregulated with MBLAC1 depletion, while cyclin E levels were reduced compared to controls. Notably for CPSF73 depletion, cyclins D1 and E showed intermediate levels compared to MBLAC1 depletion and controls ([Figure 3B](#fig3){ref-type="fig"}). Given the strong correlation between S-phase and histone biosynthesis ([@bib25]; [@bib17]), histone H3 levels were used to analyse RD histone protein abundance in MBLAC1 and CPSF73 depleted cells. Notably, H3 levels were reduced in MBLAC1 depleted cells; by contrast, CPSF73 depletion showed an intermediate H3 level compared to controls ([Figure 3B](#fig3){ref-type="fig"}). A more severe phenotype was observed in an MBLAC1 stable knockdown ([Figure 3A right graph, C, D](#fig3){ref-type="fig"}) ([Figure 3---figure supplement 2A--C](#fig3s2){ref-type="fig"}) generated in HeLa cells by CRISPR/Cas9 gene editing. This observation supports a specific role for MBLAC1 in cell cycle regulation, in particular on entering/progressing through S-phase ([Figure 3A right graph, C](#fig3){ref-type="fig"}). As for the siRNA-mediated knockdown experiments, CRISPR/Cas9 depletion of MBLAC1 results in an altered production of cyclin E and reduced level of H3. By contrast, cyclin D1 levels appear unchanged, possibly due to a mechanism of cellular adaptation under unfavourable conditions ([Figure 3D](#fig3){ref-type="fig"}).

![Loss of MBLAC1 impairs normal entrance to S-phase and S-phase progression.\
(**A**) Comparative quantification of BrdU-positive cells corresponding to early-S cells in MBLAC1 and CPSF73-depleted cells and MBLAC1 CRISPR KD (CRISPR/Cas9 mediated KD) cells after synchronization. Control siRNA (siLUC) transfected cells and wt HeLa cells were used for comparison. Error bars represent SEM from three independent biological replicates. Asterisks indicate the statistical significance using the two way ANOVA tool followed by the Bonferroni multiple comparison tool in Graphpad Prism five software: \*, p\<0.05; \*\*, p\<0.001; \*\*\*, p\<0.0001. Unlabeled variations were considered not statistically relevant. (**B**) Western blot analyses evaluating MBLAC1 and CPSF73 knockdown efficiency and effects on cyclin D1, cyclin E and histone H3 levels. (**C**) Cell cycle analysis of MBLAC1 CRISPR/Cas9 mediated stable knockdown (CRISPR KD) cells after synchronization in early S-phase. Flow cytometry profiles obtained by double-staining with an anti-BrdU antibody (upper panels) and PI (lower panels). wt HeLa cells were used for reference. Abbreviations: ~E~S, early S-phase; ~L~S, late S-phase. (**D**) Western blot analyses evaluating MBLAC1 CRISPR/Cas9-mediated stable knockdown efficiency and effects on cyclin D1, E and histone H3 levels (with synchronised cells treated with BrdU, 30-min incubation).](elife-39865-fig3){#fig3}

Treatment of MBLAC1 CRISPR/Cas9-mediated knockdown (CRISPR KD) cells with isolated recombinant MBLAC1 partially restored the wild-type cell phenotype leading to dose-dependent increasing levels of cyclin E and histone H3 compared to untreated MBLAC1 KD cells after synchronization in early S-phase ([Figure 3---figure supplement 2D](#fig3s2){ref-type="fig"}). These observations support a direct role for MBLAC1 during S-phase of the cell cycle. The subcellular distribution of ectopically administered recombinant MBLAC1 in CRISPR/Cas9-mediated knockdown cells appears to be very similar compared to that of wild-type HeLa cells ([Figure 3---figure supplement 2E](#fig3s2){ref-type="fig"}), indicating that application of recombinant MBLAC1 partially restores the wild-type like phenotype by localizing to the correct cellular compartment during S-phase.

MBLAC1 is involved in histone-specific pre-mRNA processing in vivo {#s2-3}
------------------------------------------------------------------

Given the established role of CPSF73 as a nuclear ribonuclease responsible for pre-mRNA 3ʹ end maturation ([@bib12]; [@bib36]), we investigated such a role for MBLAC1. MBLAC1 was depleted in HeLa cells using siRNA as, for comparison, was CPSF73 ([Figure 4A](#fig4){ref-type="fig"}). To evaluate not only the polyadenylated mRNA population (polyA), but also RD histone mRNA (SL) processing, cells were synchronised in early S-phase and chromatin associated RNA was extracted to capture nascent transcripts ([@bib43]). Chromatin RNA-seq (ChrRNA-seq) analyses for a typical polyA mRNA encoding gene, for example glyceraldehyde-3-phosphate dehydrogenase (GAPDH), displayed clear transcription termination defects downstream of the transcription end site (TES) in CPSF73, but not MBLAC1, depleted cells, nor in a siRNA controls ([Figure 4B](#fig4){ref-type="fig"}; [Figure 4---figure supplement 1A](#fig4s1){ref-type="fig"}). Unexpectedly, RD histone genes (SL) showed apparent transcription termination defects, not only in CPSF73, but also in MBLAC1, depletions ([Figure 4C](#fig4){ref-type="fig"}; [Figure 4---figure supplement 1B](#fig4s1){ref-type="fig"}). Importantly, 43 non-overlapping RD histone genes were analysed; of these 29 RD histone genes manifested clear transcription termination defects, in both the MBLAC1 and CPSF73-depleted samples (evidence for/exceptions are HIST1H2AI and HIST4H4 genes on which CPSF73 depletion apparently does not show an effect); a possible effect was observed on 7 RD histone genes ([Figure 4---figure supplements 2](#fig4s2){ref-type="fig"},[3](#fig4s3){ref-type="fig"}), and no apparent effect was detected on seven remaining RD histone genes ([Figure 4---figure supplements 2](#fig4s2){ref-type="fig"},[4](#fig4s4){ref-type="fig"}). Where observed, read through (RT) transcripts corresponding to this defect were detectable covering \~200 bases downstream of the transcription end site (TES) with the RD histone genes ([Figure 4---figure supplements 2](#fig4s2){ref-type="fig"},[3](#fig4s3){ref-type="fig"}). The comparison of the read through of MBLAC1 to that of CPSF73 depletion shows a similar transcription termination defect pattern affecting similar genes with a few exceptions ([Figure 4---figure supplements 2](#fig4s2){ref-type="fig"},[4](#fig4s4){ref-type="fig"}); it is possible that both MBLAC1 and CPSF73 may affect overlapping sets of histone genes, but to different extents.

![Loss of MBLAC1 leads to 3ʹ end processing defects in replication dependent histone pre-mRNA.\
(**A**) Western blots showing the knockdown efficiency of siRNA treatments for MBLAC1 and CPSF73 in synchronised HeLa cells (using β-actin as a control). (**B, C**) ChrRNA-seq analyses from one of two biological replicates (Set2), on GAPDH or selected RD histone (HIST1H2BC) genes (UCSC Genome Browser) ([@bib29]), following MBLAC1 or CPSF73 depletion. Arrows indicate gene bodies and transcription termination defect orientation. (**D**) Real-time qPCR quantification of 3ʹ end transcription termination defect following MBLAC1 and CPSF73 depletion on genes as in (**b, c**). Relative abundance (RA) of unprocessed RNA was normalised to the abundance of GAPDH mRNA (black), or to that of the corresponding histone gene body (white) ([Table 2](#table2){ref-type="table"}). Error bars represent SEM from four biological replicates. Asterisks indicate the statistical significance observed using the two-tailed *t*-test (\*\*p\<0.01). Abbreviations: GB, gene body; RT, read through; TES, transcription end site. (**E**) Real Time-qPCR quantification of 3ʹ end transcription termination defect in the MBLAC1 CRISPR/Cas9-mediated stable knockdown (KD) compared to wt HeLa cells. The relative abundance (RA) of unprocessed RNA was normalised to GAPDH mRNA (black), or to the corresponding histone gene body abundance (white) ([Table 2](#table2){ref-type="table"}). Error bars represent SEM from four biological replicates. Asterisks indicate the statistical significance observed using the two-tailed *t*-test (\*,p\<0.05, \*\*, p\<0.01, \*\*\*, p\<0.001). Unlabeled variations were considered likely not statistically relevant. (**F**) RNA-Chromatin immunoprecipitation (RNA-ChIP) analyses investigating the recruitment of MBLAC1 on histone RNA. RNA-ChIP signals are shown for MBLAC1 and FLASH in the MBLAC1 C-terminal FLAG knock in HeLa cells; the FLAG background signal is shown in wild-type cells used as control for comparison. Note that both MBLAC1 and FLASH signals are comparable on normal protein coding RNA (GAPDH). Error bars represent SEM from three (MBLAC1) or two (FLASH) biological replicates. (**G**) RNA-ChIP input samples relative comparison. Histone mRNA relative abundance (in both wild-type and MBLAC1 C-terminal FLAG knock HeLa cells) was normalised to the abundance of GAPDH mRNA in the corresponding sample. The observed results imply that the RD histone mRNA levels are not affected (within detection limits) by the tagging of MBLAC1. Error bars represent SEM from three biological replicates.](elife-39865-fig4){#fig4}

Quantitative reverse transcription PCR (RT-qPCR) analyses validated the transcriptomics results. With normal protein-coding mRNA (GAPDH), transcription termination was substantially affected by CPSF73, but not MBLAC1, depletion ([Figure 4D](#fig4){ref-type="fig"}). The abundance of termination defective (3ʹ end extended) RD histone mRNA increased in both MBLAC1- and CPSF73-depleted cells compared to controls ([Figure 4D](#fig4){ref-type="fig"}) supporting the proposal that MBLAC1 is a RD histone selective pre-mRNA processing enzyme. Consistent with this proposal, the relative levels of defective transcripts quantified by RT-qPCR analyses reflected the difference observed during ChrRNA-seq analyses between different replication-dependent histone genes (e.g. a stronger defect was observed on HIST1H2BC, compared to HIST4H4, mRNA) ([Figure 4C,E](#fig4){ref-type="fig"}; [Figure 4---figure supplement 2B](#fig4s2){ref-type="fig"}).

Single gene analyses on chrRNA confirmed the increased abundance of termination defective (3ʹ end extended) RD histone mRNA in MBLAC1 CRISPR/Cas9-mediated knockdown cells compared to wildtype HeLa cells, after synchronization in early S-phase ([Figure 4E](#fig4){ref-type="fig"}). This result supports the observed altered cell cycle phenotype as observed following depletion of MBLAC1 using siRNA ([Figures 2](#fig2){ref-type="fig"} and [3](#fig3){ref-type="fig"}). To investigate the nature of these defective transcripts, total RNA extracted from early S-phase synchronised HeLa cells (wildtype and the MBLAC1 CRISPR/Cas9-mediated knockdown) was used to evaluate the accumulation of defective histone pre-mRNAs in either the polyadenylated (polyA+) or unpolyadenylated (polyA-) RNA cellular fractions ([Figure 4---figure supplement 1C--E](#fig4s1){ref-type="fig"}). Quantitative reverse transcription PCR (RT-qPCR) analyses showed a low (\~15%), but consistent, increase in polyA +histone transcripts in MBLAC1-depleted cells compared to wild-type cells ([Figure 4---figure supplement 1C](#fig4s1){ref-type="fig"}). By contrast, in both wild-type and MBLAC1-depleted cells, the polyA- fraction showed a similar, or reduced, abundance of histone transcripts. These observations support previous studies ([@bib58]; [@bib49]; [@bib27]), by implying that RD histone pre-mRNA can undergo polyadenylation when inefficiently processed at their normal 3\' processing site.

To further investigate the involvement of MBLAC1 in RD histone pre-mRNA cleavage in vivo, RNA-Chromatin immunoprecipitation (RNA-ChIP) experiments ([@bib59]) ([Figure 4F--G](#fig4){ref-type="fig"}) were carried out using a C-terminal FLAG tagged MBLAC1 knock in generated in HeLa cells by CRISPR/Cas9 technology ([Figure 3---figure supplement 2F, G](#fig3s2){ref-type="fig"}). The results provided evidence that MBLAC1 specifically associates with chromatin associated histone mRNA during early S-phase, but that it either does not interact, or interacts to a lesser extent (similarly to FLASH) ([Figure 4F--G](#fig4){ref-type="fig"}), with normal protein coding mRNA (GAPDH); a similar amount of FLASH was recruited on histone RNA compared to MBLAC1. FLASH was used as control in our experiments as it is a well-established component of the histone 3′ end processing complex ([@bib40]) ([Figure 4F](#fig4){ref-type="fig"}). Note that RD histone mRNA relative levels are not affected by the tagging of MBLAC1 as observed by comparison of wild-type and MBLAC1 C-terminal FLAG knock HeLa cells RNA-ChIP input samples ([Figure 4G](#fig4){ref-type="fig"}).

MBLAC1 shows endoribonucleolytic activity in vitro {#s2-4}
--------------------------------------------------

The combined observations described above indicated that MBLAC1 is a ribonuclease, which is possibly involved in RD histone pre-mRNA processing. We therefore purified recombinant wild-type MBLAC1 (wtMBLAC1) and a H196A/D221A/H263A variant (mutMBLAC1) (with disrupted zinc ion binding) ([Figure 5A--B](#fig5){ref-type="fig"}) from *E. coli*, as well as wtMBLAC1 produced in HEK293 cells. These protein preparations were tested for ribonuclease activity using an internally α ^32^P UTP labeled RNA substrate corresponding to a 350 nt 3\' positioned fragment of the human HIST2H3C gene, including its 3\' processing elements ([Figure 5C--D](#fig5){ref-type="fig"}). Recombinant wtMBLAC1 purified from *E. coli* bacteria displayed significant nonspecific ribonucleolytic activity, degrading the substrate in a time dependent manner. By contrast, mutMBLAC1 manifested very little activity over time under the same assay conditions. Notably, the endoribonucleolytic activity of wtMBLAC1 purified from HEK293 cells using the same α ^32^P UTP-labeled histone RNA fragment gave an apparently more specific cleavage pattern. In particular, cleavage products corresponding in size to the biologically authentic 5\' and 3\' fragments were manifested ([Figure 5C](#fig5){ref-type="fig"}) (shown by red arrows). This apparently more specific cleavage by wtMBLAC1 when produced in HEK293 cells may reflect different kinetic properties, possibly resulting from post-translational modifications, or more biologically correct metal complexation at the active site ([Figure 1C](#fig1){ref-type="fig"}). Note that bacterial MBLfold hydrolases are active with Zn (II) and other transition metals including Fe (II) ([@bib6]). To further exclude the possibility of contaminating nuclease activity in our protein preparations and therefore validate MBLAC1 endoribonucleolytic activity, the previously described RNA substrate was also incubated with wtMBLAC1 and the H196A/D221A/H263A variant (mutMBLAC1) purified from HEK293 cells ([Figure 5D](#fig5){ref-type="fig"}). Consistent with the previous results using bacterial produced enzymes, we observed little residual activity when the substrate was incubated with mutMBLAC1 compared to wtMBLAC1. We again observed a more specific cleavage pattern with wtMBLAC1 from HEK293 cells rather than with the bacterial produced wtMBLAC1 ([Figure 5D](#fig5){ref-type="fig"}).

![MBLAC1 has sequence-specific endoribonucleolytic activity on RD histone pre-mRNA.\
(**A**) Silver staining analyses showing purity of MBLAC1 protein preparations produced from different sources. Note all proteins are highly purified except mutMBLAC1 produced in HEK293 which presents some contaminants. (**B**) Schematic view of metal binding and active site residues and the two water molecules (red spheres) observed to coordinate (black dashed lines) to the metals (grey spheres) at the MBLAC1 active site by crystallography (numbering as in [Figure 1](#fig1){ref-type="fig"}). Active site residues substituted to alanine in the MBLAC1 variant (H196A/D221A/H263A) are in red. (**C**) Time-dependent in vitro cleavage assay using an internally labeled \[^32^P\] histone 2H3C pre-mRNA fragment (350 nt) with *E. coli* produced wtMBLAC1, or an active site substituted MBLAC1 variant (H196A/D221A/H263A), or HEK293 produced wtMBLAC1 (media secreted). Note only a fraction of the total RNA is hydrolyzed. (**D**) Time-dependent in vitro cleavage assay using an internally labeled \[^32^P\] histone 2H3C pre-mRNA fragment (350 nt) with HEK293 produced wtMBLAC1, or an active site substituted MBLAC1 variant (H196A/D221A/H263A). The red arrows indicate the assigned position of 3\' end processing in vivo. Note that both wt and mutMBLAC1 used in this experiment were purified from HEK293 cell lysates instead of from cell media due to the loss of secretion of the mutant enzyme in the cell media. (**E**) Schematic view of the histone 2H3C pre-mRNA fragment (168 nt) used in the cleavage assays showing preferential cleavage occurs after the CA dinucleotide located five nucleotides to the 3\' side of the stem loop. The single-nucleotide substitution (A/G) at the CA cleavage site is shown. (**F**) Time dependence of *E. coli* produced wtMBLAC1 in vitro cleavage using an internally labeled \[^32^P\] unmodified (WT RNA), or with a single-nucleotide substituted (MUT RNA) histone pre-mRNA fragment (as in E). The red arrows indicate the assigned position of 3\' end processing in vivo. Abbreviations: HDE, histone downstream element; SL, stem loop.](elife-39865-fig5){#fig5}

We next investigated the potential cleavage specificity of MBLAC1 using a shorter α ^32^P UTP internally labeled RNA substrate (WT RNA) and a variant with a single-nucleotide substitution (A/G) at the major physiological histone pre-mRNA processing site (MUT RNA) ([Figure 5E](#fig5){ref-type="fig"}) ([@bib19]; [@bib30]). Bacterially produced wtMBLAC1 showed clear ribonucleolytic activity with the WT RNA substrate in a time-dependent manner ([Figure 5F](#fig5){ref-type="fig"}). Major cleavage products were observed (red arrow) at positions corresponding to the authentic 3\' processing position. However, little evidence for ribonucleolytic activity was observed when wtMBLAC1 was incubated with MUT RNA ([Figure 5F](#fig5){ref-type="fig"}). This observation suggests that MBLAC1 specifically recognises the biologically authentic CA dinucleotide required for histone pre-mRNA maturation and that this site is critical for recognition/initial cleavage/binding by MBLAC1. Mononucleotides were not observed to accumulate under any of the tested conditions (data not shown) implying a lack of exonucleolytic activity for MBLAC1. Thus, consistent with the crystallographically observed structural similarity between MBLAC1 and LACTB2 ([@bib34]) ([Figure 1H](#fig1){ref-type="fig"}), these results identify MBLAC1 as a ribonuclease with endonucleolytic activity. Unlike purified CPSF73 ([@bib36]), which exhibits substantially sequence-independent ribonuclease activity, isolated MBLAC1 appears more sequence selective especially with shorter RNA substrates ([Figure 5F](#fig5){ref-type="fig"}). These observations imply that, at least in isolated form, MBLAC1 initially catalyses hydrolysis at the biologically validated CA cleavage site with subsequent endonucleolytic cleavage occurring at other positions.

RNA elements required for MBLAC1 specific activity in vitro {#s2-5}
-----------------------------------------------------------

Specific elements are required for maturation of histone pre-mRNA in vivo ([@bib40]); in particular, SLBP appears to be necessary for efficient processing through stabilization of the HDE-U7 snRNA interaction and the HLF complex involving symplekin, CPSF73, CPSF100, and CstF64, which are required for the cleavage of the pre-mRNA ([@bib11]; [@bib31]; [@bib49]). To investigate the specificity of the observed MBLAC1 hydrolytic activity on histone pre-mRNA, 50 to 40 nucleotide RNA fragments corresponding to a portion of the RD human histone HIST2H3C pre-mRNA were \[γ-^32^P\] ATP 5\' labeled and incubated with wtMBLAC1 produced in HEK239 cells (50 ng) ([Figure 6](#fig6){ref-type="fig"}). The reaction catalysed by MBLAC1 on the wild-type RNA 1 generated two main products assigned as 27 and 29 nucleotides long (based on our fragment numbering system), corresponding to the 'physiological' major and minor cleavage sites ([@bib56]; [@bib19]), respectively ([Figure 6A](#fig6){ref-type="fig"}). This observation is in agreement with previous studies, where the major and minor cleavage sites were reported to occur 5 and 7 nucleotides after the stem-loop, respectively, that is ACCCA corresponding to cleavage in position 27, and ACCCACA corresponding to cleavage in position 29 ([@bib50]; [@bib19]). When a single nucleotide in RNA 1 is mutated at position 27 (A/G), to abolish the 'physiological' CA dinucleotide at this position (RNA 2), we observed production of a single main processing product corresponding to cleavage at position 29 ([Figure 6A](#fig6){ref-type="fig"}). Although hydrolysis of RNA 2 was clearly observed, it appeared less efficient compared to that of RNA 1. This observation is in agreement with the results described above where a single point mutation at position 27 negatively affects catalysis ([Figure 5F](#fig5){ref-type="fig"}). mutMBLAC1 purified from HEK293 cells was also tested using RNA 2 to investigate its ability to hydrolase the substrates at specific positions; as anticipated, mutMBLAC1 showed very little hydrolytic activity on RNA 2 compared to wtMBLAC1 ([Figure 6B](#fig6){ref-type="fig"}). To further investigate the specificity of cleavage after the CA at position 27, the wild-type RNA was modified to contain only one CA dinucleotide at position 27 (RNA 3). Incubation with MBLAC1 led to the production of a single observed degradation product consistent with cleavage at position 27 (major cleavage site), but again with apparently impaired efficiency ([Figure 6C](#fig6){ref-type="fig"}). When the nucleotide sequence of the stem-loop was inverted, to maintain secondary structure (RNA 4), the cleavage reaction appeared less efficient, although the cleavage specificity was apparently not compromised within our limits of detection (note that the processing products of RNA 4 has a slower electrophoretic mobility) ([Figure 6D](#fig6){ref-type="fig"}). This observation suggests the precise stem-loop sequence composition does not affect the correct positioning of MBLAC1 at the physiological CA cleavage site. When the stem-loop sequence was modified to ablate its conformation (RNA 5), cleavage at position 27 (the major cleavage site) was apparently completely abolished; instead, a major band was observed corresponding to cleavage at the CA, position 23, although longer degradation fragments were also detected (consistent with cleavage at positions 29, and possibly 32, 35) ([Figure 6E](#fig6){ref-type="fig"}). The degradation patterns observed for RNA 4 and 5 imply that likely the stem-loop structure prevents MBLAC1 from accessing putative single-stranded cleavage sites located upstream of position 27, thus helping to maintain specificity of cleavage at position 27. MBLAC1 activity was also evaluated on a fragment lacking the HDE sequence (RNA 6); interestingly, with this substrate efficient cleavage was maintained and the major cleavage site (position 27) still recognised, although the cleavage specificity was reduced, leading to the formation of additional degradation bands corresponding to hydrolysis at all the CA dinucleotides present in the fragment 6 sequence ([Figure 6F](#fig6){ref-type="fig"}). Overall, these results support the proposal that purified MBLAC1 displays significant histone mRNA 3\' end processing specificity.

![MBLAC1 shows specific endoribonucleolytic activity on histone pre-mRNA recognising specific sequence/structural RNA elements in vitro.\
(**A, C--F**) Time-dependent in vitro cleavage assays using \[γ-^32^P\] ATP 5\' labeled histone 2H3C RNA fragments (RNA 1--6) in the presence of HEK293 produced wtMBLAC1. (**B**) Time-dependent in vitro cleavage assays using \[γ-^32^P\] ATP 5\' labeled histone 2H3C RNA 2 (50 nt) in the presence of HEK293 produced wild-type or mutMBLAC1. Cleavage products of RNA 2 after incubation with wtMBLAC1 (WT) are compared with those after incubation with mutMBLAC1 (MUT). Cleavage products of the RNA 1 are compared with those of the differently modified fragments. Schematic views of the RNA fragments are shown. The schematics show the numbering assigned to the possible cleavage sites present in each RNA; arrows indicate the physiologically major (red) and minor (blue) cleavage sites. The CA dinucleotide corresponding to the major cleavage site is in red. Sequence or structural modifications of each RNA are in yellow. The size of processed RNA products is indicated when appropriate. Unprocessed RNA fragments corresponding to nucleotides 1 to 29 and 1 to 27 of the WT RNA 1 were used as mass markers and indicated as 29 and 27, respectively. Note that the 29 and 27 markers migrate more slowly on gel electrophoresis compared to the corresponding fragments generated by MBLAC1 catalysis in positions 27 and 29. This observation is explained by the presence of an extra negatively charged phosphate group on the 5\'end of the products generated by MBLAC1 catalysis, compared to the markers, as expected during maturation of histone transcripts ([@bib19]).](elife-39865-fig6){#fig6}

Discussion {#s3}
==========

The combined biochemical, cellular, and genetic analyses presented here provide clear evidence that MBLAC1 is an endoribonuclease selective for 3\' end processing of RD histone pre-mRNA during S-phase of the cell cycle. Assays with isolated recombinant MBLAC1 reveal it is selective for hydrolytic cleavage at the biologically relevant CA dinucleotides present 5 and 7 nucleotides downstream of the stem-loop sequence in replication-dependent pre-mRNA (positions 27 and 29, respectively, using our pre-mRNA numbering). Crystallographic and other biophysical analyses support the assignment of MBLAC1 as a nuclease, which is related to CPSF73 in terms of the overall fold of its MBL domain, but which has distinctive, structural features, possibly reflecting their different substrate recognition and/or substrate binding modes ([Figure 1](#fig1){ref-type="fig"} and [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}).

The results obtained by depletion of MBLAC1 using siRNA or CRISPR/Cas9 techniques support the involvement of MBLAC1 in RD histone pre-mRNA processing in vivo. The slow growth rate of MBLAC1-depleted cells ([Figure 3---figure supplement 2](#fig3s2){ref-type="fig"}) likely reflects its important role in RD histone pre-mRNA processing which is required for normal progression through the cell cycle. The observation of a cell cycle defect in entering/progressing through S-phase correlates with reduced histone protein abundance in HeLa cells after depletion of MBLAC1, either using siRNA or CRISPR/Cas9 ([Figure 3](#fig3){ref-type="fig"}). These results are in agreement with a defect in efficient histone pre-mRNA maturation as we observed by chrRNA-seq analyses in HeLa cells depleted of MBLAC1 where RD histone pre-mRNA transcripts manifested abnormally 3\' end extensions reflecting inefficient maturation. The inability of MBLAC1-depleted cells to produce the appropriate amount of histone proteins due to the lack of mature mRNA encoding for them is also consistent with occurrence of a 'G~1~-like' block, as observed by flow-cytometry and western blot analyses ([Figure 3](#fig3){ref-type="fig"} and [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}). These results imply that during S-phase, MBLAC1 has a specialised role in RD histone pre-mRNA processing.

Studies with recombinant MBLAC1 purified from human or *E. coli* cells, define MBLAC1 as an endoribonuclease, with selectivity for cleavage at the biologically authentic CA dinucleotides (positions 27 and 29 using our nomenclature, [Figure 6](#fig6){ref-type="fig"}). These results imply that the stem-loop secondary structure of RD nascent pre-mRNA is involved in enabling preferential cleavage at position 27. The presence of the HDE sequence appears to be required to avoid non-specific cleavage, although cleavage at position 27 was still observed when the HDE was removed ([Figure 6F](#fig6){ref-type="fig"}). The involvement of the HDE element in determining selectivity is supported by in vitro studies utilizing HeLa nuclear extracts indicating that the HDE is a major factor in defining the cleavage site of RD histone pre-mRNA ([@bib50]). The work with isolated MBLAC1 reveals that it has potential to catalyse cleavage at CA sites other than at positions 27 and 29, although the biological relevance of these other reactions needs to be validated. Future work can also focus on establishing the details of the kinetics of MBLAC1 catalysis and the structural features that enable its selectivity, including the nature of its interactions with the stem-loop and the HDE element at the 3\' end of RD histone pre-mRNA.

Further detailed work is required to compressively define the factors responsible for targeting MBLAC1 to the RD histone pre-mRNA cleavage site. The available results indicate that it is possible that the observed in vitro sequence specificity of MBLAC1 may enable recognition of core histone pre-mRNA substrates without the requirement for as many additional factors as is necessary in the case of CPSF73 (or that MBLAC1 requires different factors) ([@bib58]).

Consistent with previous reports ([@bib12]; [@bib31]; [@bib57]), we found that CPSF73 promotes RD histone pre-mRNA processing. However, it is likely that CPSF73 is relatively more important than MBLAC1 in RD histone pre-mRNA processing outside of S-phase, reflecting its essential role in the biosynthesis of polyadenylated mRNA, including that of multiple histone variants ([@bib39]; [@bib38]; [@bib61]). CPSF73 could well also be wholly or partly responsible for processing of defective RD histone pre-mRNA that subsequently undergoes polyadenylation ([@bib58]) when MBLAC1 is depleted in cells. Reported biochemical work with CPSF73 in its isolated form has only been carried-out with few histone pre-mRNA model sequences ([@bib30]). Thus, it is possible that both CPSF73 and MBLAC1 selectively impact on the rates of maturation of different histone pre-mRNA substrates in vivo, opening up the possibility for selective modulation of the biosynthesis of RD histone variants. Although further validation work is required, our observations in cells support also the proposal that MBLAC1 and CPSF73 impact to different extents on similar genes, possibly compensating for depletion of one another in cells ([Figure 4---figure supplement 2](#fig4s2){ref-type="fig"}).

Our genetic and cellular studies imply that MBLAC1 inhibition may selectively slow down S-phase progression in cancer cells. Thus, MBLAC1 may represent a new S-phase specific cancer target. The true bacterial MBLs involved in antibacterial resistance have been shown to be amenable to small molecule targeting ([@bib44]), and it is likely that human MBL-fold endonucleases will also be sensitive to small molecule inhibition. Our results suggest that targeting MBLAC1 may not be as toxic as CPSF73, which has a pleiotropic role in polyadenylated pre-mRNA processing ([@bib36]). Thus, the development of MBLAC1 inhibitors, likely for use in combination with other drugs, is of interest from the cancer treatment perspective. Finally, it is notable that relatively non-selective zinc ion chelating compounds, including HDAC inhibitors such as SAHA (suberanilohydroxamic acid) ([@bib62]), are already used for cancer treatment via S-phase targeting. It is possible that these, at least in part, work by inhibiting metal dependent endoribonucleases, such as CPSF73 and MBLAC1.

Materials and methods {#s4}
=====================

Reagents and antibodies {#s4-1}
-----------------------

Unless otherwise specified, reagents were from *Sigma-Aldrich*. Antibodies used were: goat anti- MBLAC1 (sc-243427), HRP-conjugated donkey anti-goat (sc-2020), goat anti-Lamin B1 (sc-30264), mouse anti-Cyclin D (sc-20044), mouse anti-Cyclin E (sc-247) (all from *Santa Cruz Biotechnology, Inc.*); rabbit anti-MBLAC1 (ARP70842_P050) (*Aviva System Biology*); mouse anti-His tag (ab18184), rabbit anti-His tag (ab9108), mouse anti-Histone H3 (ab10799), HRP-conjugated mouse anti-β-actin (ab49900) (all from *Abcam*); HRP-conjugated goat anti- rabbit (170--6515) (*Biorad*); rabbit anti-CPSF73 (A301-091A) (*Bethyl Laboratories, Inc,*); mouse anti-Lamin A/C (4777) (*Cell Signaling Technology*); mouse anti-FLAG M2 (F3165) and mouse anti-α-tubulin (T5168) (*Sigma-Aldrich*); HRP-conjugated goat anti-mouse (W402B) (*Promega Corporation*); FITC mouse anti-BrdU (364104) (*BioLegend Inc.*). *Alexa fluor* secondary antibodies used in immunofluorescence microscopy experiments were from *Molecular Probes* (*Thermo Fisher Scientific*).

Recombinant MBLAC1 production in *E. coli* and purification {#s4-2}
-----------------------------------------------------------

cDNA (codon optimised for expression in *E. coli*) encoding for MBLAC1 (*GeneART*, *Thermo Fisher Scientific*) was inserted into the pCOLD I vector (*Addgene*) in order to produce MBLAC1 with an *N*-terminal hexa-histidine tag (6xHis) with an *N*-terminal C human rhinovirus (HRV3C) protease cleavage site. Recombinant MBLAC1 protein was produced in *E. coli* BL21 (DE3) cells grown in 2TY growth media with 50 µg/mL ampicillin at 37°C to mid-exponential phase (OD 600 = 0.6--0.8). MBLAC1 production was induced by addition of isopropyl β-D-1-thiogalactopyranoside (IPTG) (0.5 mM) supplemented with 50 µM zinc sulfate while incubating at 15°C. Cells were harvested by centrifugation (6500 x g, 8 min) after 18 hr and frozen in liquid nitrogen. The cell pellet (\~20 g) was added to 100 mL of lysis buffer (20 mM 4-(2-hydroxyethyl)−1-piperazineethanesulfonic acid (HEPES), pH 7.5, 500 mM sodium chloride, 5 mM imidazole), lysed by sonication followed by centrifugation (20,000 x g, 20 min). MBLAC1 was purified by loading the supernatant onto a 5 mL Ni-affinity column (*GE Healthcare*). The equilibration buffer was the same as the lysis buffer. The elution buffer additionally contained 500 mM imidazole and was used to form an imidazole gradient (from 5 to 500 mM) to elute the His-tagged protein. MBLAC1 was then loaded onto a S200 (300 mL) gel filtration column using 20 mM HEPES, pH 7.5, 500 mM sodium chloride as the running buffer. Fractions containing protein were analysed by SDS-PAGE. The 6x-His tag was cleaved by addition of HRV3C protease (overnight incubation at 4°C), then purified by Ni-affinity chromatography to remove the cleaved tag. The resultant purified MBLAC1 (\~27 kDa) was buffer exchanged into 25 mM HEPES, pH 7.5, 30 mM sodium chloride, then concentrated to 23 mg/mL using a Centricon concentrator (10 k MW cutoff) (*Merck*) (at 3000 x g) until the desired volume was achieved.

Crystallization and structure determination {#s4-3}
-------------------------------------------

Crystallization was performed using the sitting drop vapor diffusion method using *Art Robbins* 96 well - three subwell Intelliplates and a protein:well drop size of 200 nL:100 nL,100 nL:100 nL, 100 nL:200 nL for each subwell condition. MBLAC1 crystallised over \~24 hr using the following conditions: JCSG-*plus* condition 94, 0.1 M bis Tris pH 5.5, 0.2 M ammonium acetate, 25 % w/v PEG 3350 (protein to reservoir ratio 2:1, 1:1, and 1:2) (*Molecular Dimensions*). Crystallization conditions were optimised by varying the ammonium acetate concentration (0.14--0.25 M) and PEG 3350 percentage (23--30%). The resultant crystals (\~150×300 µm) obtained in 0.1 M Bis Tris pH 5.5, 0.18 M ammonium acetate, and 25 % w/v PEG 3350, were cryo-protected in well-solution diluted to 12.5% sucrose for 30 s, then harvested using nylon loops followed by cryo-cooling and storage under liquid nitrogen. Data were collected on a single crystal at 100 K at the Diamond Light Source Synchrotron (beamline I04, 1.28268 Å wavelength) to 1.8 Å resolution. Data were autoprocessed at the beamline using XDS ([@bib26]) and CCP4-SCALA ([@bib16]) in XIA2 ([@bib63]). The MBLAC1 structure was solved by molecular replacement (MR) using the PHASER subroutine within PHENIX ([@bib47]; [@bib1]; [@bib2]) with an ensemble structure as a search model based on 11 crystal structures identified by the Phyre two modelling server ([@bib28]) using the MBLAC1 protein sequence as search input. Refinement was carried out by iterative rounds of model building using Coot ([@bib15]) and maximum likelihood restrained refinement using PHENIX ([@bib3]). Ramachandran statistics calculated 98.27% most favored geometry, 1.61% additionally allowed and 0.12% outliers. Data collection, processing, and structure refinement statistics are given in [Table 1](#table1){ref-type="table"} (related to [Figure 1](#fig1){ref-type="fig"}).

Non-denaturing electrospray ionization mass spectrometry {#s4-4}
--------------------------------------------------------

MBLAC1 purified from *E. coli* was diluted to 15 µM in 15 mM ammonium acetate buffer (pH 7.5). The cone voltage for the acquisition of the spectra was 80 V. Electrospray ionization mass spectra of the *apo*-enzyme were acquired in the positive ionization mode after overnight metal removal treatment by addition of 20 mM ethylenediaminetetraacetic acid (EDTA) to the protein solution.

Inductively coupled plasma mass spectrometry (ICP-MS) {#s4-5}
-----------------------------------------------------

Wild-type MBLAC1 was produced in *E. co*li or HEK293 cells; 30 µg of the resultant purified protein was then buffer exchanged into 20 mM HEPES pH 7.5, 50 mM NaCl buffer prepared using 'ultrapure' water. Concentrations of Zn, Fe, Mn, Ni, and Co divalent ions were measured in triplicate. ICP-MS experiments and data analysis were carried out by the ICP-MS Trace Element Small Research Facility of the Earth Sciences Department, Oxford University.

Cell culture and transfection {#s4-6}
-----------------------------

HeLa (*ATCC*) and HEK293 (kindly provided by Prof. Peter McHugh) cells were cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum, and 2 mM L-glutamine, at 37°C in a humidified incubator (5% CO~2~). To generate the construct MBLAC1 6xHis-pCDNA 3.1, an appropriate sequence coding for MBLAC1 (*GeneART*, *Thermo Fisher Scientific*) was amplified by PCR to introduce a C-terminal 6xHis tag, then cloned into the pCDNA 3.1 vector (*Invitrogen*). Both HeLa and HEK293 cells were transiently transfected with the MBLAC1 6xHis-pCDNA3.1 construct using the Fugene HD transfection reagent (*Promega*), following the manufacturer's instructions. MBLAC1 production was monitored by western blotting, 24 and 48 hr after transfection. To generate a stable cell line overexpressing MBLAC1, HEK293 cells were transfected with the MBLAC1 6xHis-pCDNA 3.1 construct using the Fugene HD transfection reagent (*Promega*), following the manufacturer's instructions. Stably transfected cells were selected by addition of geneticin (G418) (1 mg/ml) to the cell culture media; cell clones were generated by limiting dilution plating. Clones were analysed by western blotting for their capacity to produce MBLAC1.

HEK293 expressed MBLAC1 production and purification {#s4-7}
---------------------------------------------------

The best producing MBLAC1 HEK clone (c27) was adapted to serum-free growing conditions (*Free style* medium, *Invitrogen*) and cultivated in spinning culture at 37°C in a humidified incubator (8% CO~2~) in the presence of 20 μM heparin sodium salt. Cell medium containing secreted 6xHis-tagged MBLAC1 was harvested every 48 hr and stored at −20°C until used. For purification, 10 mM imidazole was added to 1 L of clarified cell medium before loading onto a 1 mL Ni-affinity column (GE Healthcare) equilibrated with 25 mM HEPES, pH 7.5, 500 mM sodium chloride, 10 mM imidazole. The elution buffer additionally contained 500 mM imidazole and was used to form an imidazole gradient (from 10 to 500 mM) to elute the His-tagged protein. Fractions containing protein were analysed by SDS-PAGE. The solution was concentrated to about 100 µL using a Centricon concentrator (10 k MW cutoff) (*Merck*) (at 3000 x g) and exchanged into 25 mM HEPES pH 7.5, 50 mM NaCl using 0.5 mL *Micro Biospin*^TM^*six* desalting columns (*Biorad*). The obtained protein solution was concentrated to about 5 mg/mL and its purity determined by SDS PAGE. Alternatively, wild-type HEK293 cells adapted to serum-free growing conditions (*Free style* medium, *Invitrogen*) were transiently transfected with the MBLAC1 6xHis-pCDNA 3.1 encoding constructs (for the expression of both wild-type and active site mutant MBLAC1) using the Expi293 expression system (*Thermo Fisher Scientific*), following the manufacturer's instructions. Interestingly, mutMBLAC1, unlike wtMBLAC1, was not secreted into the cell medium. Therefore both wild-type and active site mutant MBLAC1 were purified as previously described following cell lysis by sonification.

Single point mutagenesis {#s4-8}
------------------------

Site-directed residue substitutions of MBLAC1 were performed using *Pfu* Turbo DNA polymerase (*Agilent Technologies*) according to the manufacturer's protocol. Primers used to generate the mutants were designed following the manufacturer instructions and are listed in [Table 2](#table2){ref-type="table"}. The pCOLD I vector (used to overexpress MBLAC1 in *E. coli*) was employed as template DNA. Plasmid DNA with the correct mutation were used to transform *E. coli* BL21 (DE3) cells as described above. MBLAC1 mutants expressed in *E. coli* were produced and purified similarly to wild-type enzyme, as previously described.
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###### Oligonucleotide primers and single guide RNA targeting sequences used in site directed mutagenesis, RT-qPCR experiments and CRISPR/CAS9 mediated KD studies.

Abbreviations: GB, gene body; RT, read through. Note that the standard BBL numbering system has been used ([@bib20]).

  Oligonucleotide primers used for site directed mutagenesis   
  ------------------------------------------------------------ --------------------------------
  H196A_F                                                      GCAACACCGGGTGCTGGTGGTCAGCG
  H196A_R                                                      CGCTGACCACCAGCACCCGGTGTTGC
  D221A_F                                                      GTTGTTGCCGGTGCTGTTTTTGAACGTG
  D221A_R                                                      CACGTTCAAAAACAGCACCGGCAACAAC
  H263A_F                                                      GGTTGTTCCTGGTGCTGGTCCGCCTTTTCG
  H263A_R                                                      CGAAAAGGCGGACCAGCACCAGGAACAACC
  Oligonucleotide primers used in RT-qPCR experiments          
  GAPDH_GB_F (intron)                                          ACCCAGAAGACTGTGGATGG
  GAPDH_GB \_R (intron)                                        TTCAGCTCAGGGATGACCTT
  GAPDH \_RT_F                                                 TCCAGCCTAGGCAACAGAGT
  GAPDH \_RT_R                                                 TGTGCACTTTGGTGTCACTG
  HIST1H2BC_GB_F                                               ACCTCCAGGGAGATCCAGAC
  HIST1H2BC_GB_R                                               AGCTGGTGTACTTGGTGACG
  HIST1H2BC_RT_F                                               CTCCAGGGAGATCCAGACGG
  HIST1H2BC_RT_R                                               GCTCTTTTAGTGGGTATCTGGG
  HIST4H4_GB_F                                                 GAAGGTGCTGCGGGACAATA
  HIST4H4_GB_R                                                 AAGACTTTGAGGACTCCCCG
  HIST4H4_RT_F                                                 CGCGCAACGCAGTAGTGACC
  HIST4H4_RT_R                                                 CATTCAGCTTTCGGGCTTGCAGGTA
  HIST2H2AC_GB_F                                               GGCTCGGGACAACAAGAAGA
  HIST2H2AC_GB_R                                               AGAACGGCCTGGATGTTAGG
  HIST2H2AC_RT_F                                               GAAAGCCACAAAGCCAAAAGC
  HIST2H2AC_RT_R                                               GGCTTGACACCATACTCATTCACC
  HIST1H3G_GB_F                                                CTGAGCTGCTGATCCGCAAG
  HIST1H3G_GB_R                                                GGCGAGCGAGCTGAATGTCC
  GAPDH_GB_F (exon-exon)                                       AAGGTGAAGGTCGGAGTCAA
  GAPDH_GB \_R (exon-exon)                                     AATGAAGGGGTCATTGATGG
  r18S_F                                                       GGCCCTGTAATTGGAATGAGTC
  r18S_R                                                       CCAAGATCCAACTACGAGCTT
  CRISPR/Cas9 single guide RNA (sgRNA)                         
  Location                                                     sgRNA targeting sequences
  5ʹ targeting                                                 ACAGCGGCTCGGTCCGCATGAGG
  3ʹ targeting                                                 TGCACTAATCAGCCTCGAGAGGG
  CRISPR/Cas9 sequencing primers                               
                                                               Primers sequence
  CRISPR/Cas9_F                                                CAGAGAACCGAGGCTTAGGG
  CRISPR/Cas9_R                                                GAAGCTCCCACCCTTGACTG
  CRISPR/Cas9 RT-qPCR primers                                  
                                                               Primers sequence
  HSE_set1_F                                                   ATCACATCGGGAACTTGGGG
  HSE_set1_R                                                   CACCACGGTGCCCAGAG
  HSE_set2_F                                                   GCTCTGGGCACCGTGG
  HSE_set2_R                                                   GCGAGGCTTCCCTTAACACT

Subcellular fractionation {#s4-9}
-------------------------

Cytoplasmic and nuclear subcellular fractions were prepared as follows: HeLa cells were washed twice with ice-cold PBS, then suspended in harvest buffer (10 mM HEPES KOH pH 7.9, 50 mM NaCl, 0.5 M sucrose, 0.5% Triton X-100, 1 mM DTT and protease inhibitor cocktail). After incubation for 5 min on ice, cells were centrifuged (100 x g, 10 min, 4°C) to pellet nuclei. The supernatant (containing cytosolic and membrane proteins) was centrifuged (14,000 x g, 10 min, 4°C) and stored. The nuclear pellet was resuspended and washed by centrifugation in buffer A (10 mM HEPES KOH pH 7.9, 10 mM KCl, 1 mM DTT and protease inhibitor cocktail) (100 x g10 min, 4°C). The obtained nuclear pellet was resuspended in 4 volumes of buffer C (10 mM HEPES KOH pH 7.9, 200 mM NaCl, 0.1 % NP-40, 1 mM DTT and protease inhibitor cocktail) and vortexed at 4°C for 30 min. The nuclear lysate was then centrifuged (15 min at 14,000 x g at 4°C). Proteins concentrations of both cytoplasmic and nuclear fractions were measured using the Bradford reagent. The subcellular fractions were then evaluated by western blot analysis.

In vitro RNA degradation assays {#s4-10}
-------------------------------

DNA sequences coding for a portion of the human histone 2H3C (HIST2H3C) (350 nt), and the WT and MUT shorter forms of the human histone 2H3C (HIST2H3C) (168 nt) genes with a 5ʹ T7 RNA polymerase promoter sequence were used as templates to generate internally \[^32^P\] labeled RNA substrates by in vitro transcription (MEGAscript T7 Kit, *Thermo Fisher Scientific*). The reaction was carried out following the manufacturer's instructions by adding an excess of \[α-^32^P\] UTP to the reaction mixture. In vitro transcription products were fractionated on a 6% denaturing polyacrylamide/urea gel. The generation of the radiolabeled RNA substrates was monitored by autoradiography. The radiolabeled RNA was then gel purified and resuspended in 80 µL ddH~2~O. For the 5ʹ \[γ-^32^P\] ATP labeled substrates listed in [Table 1](#table1){ref-type="table"}, RNA fragments were purchased from *Integrated DNA Technologies* and 1 µg of each RNA was treated with T4 polynucleotide kinase (*New England Biolabs*) in the presence of an excess of \[γ-^32^P\] ATP. The obtained 5\' \[γ-^32^P\] ATP labeled substrates were then gel purified using a 10% denaturing polyacrylamide/urea gel and resuspended in 60 µL ddH~2~O. Cleavage assays were carried out in a mixture (10 μl) containing: 1 µL of labeled RNA substrates (\~600 ng of \[α-^32^P\] UTP substrate (\~5 µM),\~16 ng of \[γ-^32^P\] ATP fragments (\~1 µM)), 500 ng (\~15 µM) of recombinant wild-type or the active site variant MBLAC1 produced in both *E. coli* and HEK293 cells, or 50 ng (\~1.5 µM) of recombinant wild-type or the active site variant produced in HEK293 cells and 1x reaction buffer (20 mM HEPES KOH pH 7.5, 50 mM KCl, 10 mM MgCl~2~, 0.5 mM DTT, 0.05% Triton X-100, 5% glycerol) at 37°C. The reaction was stopped at the appropriate time point by phenol-chloroform extraction and ethanol precipitation. RNA degradation products were then fractionated on 6, 8 or 10% denaturing polyacrylamide/urea gel and the data were analysed by Phospho-Imager (Fujifilm FLA 5000 imager).

siRNA transfection and cell synchronization {#s4-11}
-------------------------------------------

About 50% confluent HeLa cells were transfected with a SMARTpool of siRNA for MBLAC1 or CPSF73 (*GE Dharmacon*), or with a negative control siRNA (Luciferase), using the Lipofectamine RNAiMAX transfection reagent (*Invitrogen*) following the manufacturer's instructions. Cells were transfected with a final concentration of 10 nM siRNA and knockdown efficiency was assessed 48 hr post transfection by western blot analysis. Transfected HeLa cells were synchronised using the double thymidine block method ([@bib24]). In brief, 6 hr post-siRNA transfection, cells were treated with 2 mM thymidine (final concentration) for 18 hr; the thymidine was then removed for 9 hr, and then was added again (2 mM) for 15 hr. Cells were then washed with PBS twice, and harvested at different time points after release from the block; alternatively, cells were washed with PBS twice and treated with 10 μM of 5-bromo-2\'-deoxyuridine (BrdU), for 30 min or 1 hr. BrdU treated cells were washed with PBS to remove the unincorporated BrdU and then harvested at different time points for cell cycle analysis. Similarly, wt and CRISPR/cas9 mediated MBLAC1 kd HeLa cells were synchronised and BrdU treated as described above.

Cell cycle analysis {#s4-12}
-------------------

Synchronised HeLa cells were washed with PBS buffer and fixed in ice-cold ethanol overnight. DNA was stained with a propidium iodide (PI) solution containing 0.1% Triton X-100 in PBS, 0.2 mg/ml RNase A, 0.02 mg/ml PI for 30 min at room temperature. Alternatively, BrdU-treated cells were fixed by adding ice-cold 70% ethanol overnight. Cells were then incubated with 2 N HCl, 0.5% Triton X-100 for 30 min at room temperature and washed with 0.1 M sodium tetraborate buffer, pH 8 for 2 min. Cells were washed and incubated with a FITC conjugated anti-BrdU antibody (*BioLegend*) for 1 hr at room temperature. PI staining followed as described above. Cell cycle profiles were analysed by flow cytometry with FACSCalibur (*BD Biosciences*) and processed using FlowJo software (*Tree Star*).

Chromatin RNA extraction and libraries preparation {#s4-13}
--------------------------------------------------

Chromatin RNA (ChrRNA) was extracted from HeLa cells 48 hr after siRNA transfection to coincide with the end of the second thymidine block time-point. Approximately 3 × 10^6^ cells were resuspended in 500 µL of ice-cold RLB buffer (10 mM Tris-HCl, pH 7.5, 140 mM NaCl, 0.5% nonidet-P40 (NP-40), 1.5 mM MgCl~2~) and lysed by adding an equal volume of RLB buffer with 24% (m/v) sucrose. Nuclei were collected by centrifugation (14,000 x g) at 4°C for 10 min. Isolated nuclei were resuspended in 120 µl of NUN1 buffer (20 mM Tris-HCl, pH 7.9, 75 mM NaCl, 0.5 mM EDTA, 50% Glycerol, 0.125 mM PMSF, 1 mM DTT), followed by addition of 1.2 ml NUN2 buffer (20 mM HEPES KOH pH 7.6, 7.5 mM MgCl~2~, 0.2 mM EDTA, 300 mM NaCl, 1 M urea, 1 % NP-40, 1 mM DTT). Nuclei were incubated for 15 min on ice with mixing by vortexing for 5 s every 5 min. Chromatin pellets were precipitated by centrifugation (14,000 x g) at 4°C for 10 min and then resuspended in 200 ml HSB buffer (10 mM Tris-HCl, pH 7.5, 500 mM NaCl, 10 mM MgCl~2~) in presence of 4 U TURBO DNase (*Ambion*) and incubated at 37°C for 20 min. Following a 20-min proteinase K treatment (*Roche*) at 37°C, chromatin RNA (chrRNA) was phenol-chloroform extracted and ethanol precipitated. RNA was resuspended in 200 µL of 1x TURBO DNAse buffer in presence of 4 U TURBO DNase and incubated at 37°C for 30 min. The entire procedure of extraction, precipitation and DNase treatment was repeated twice. RNA was then extracted and precipitated again, prior to solubilisation in 75 µL of RNase free water.

Prior to RNA libraries preparation, rRNA was depleted using the Ribo-Zero Magnetic kit (*Illumina*) from 2.5 µg of ChrRNA. Libraries were prepared starting from 100 ng chrRNA using the NEBNext Ultra Directional RNA Library Prep kit for Illumina (*NEB*) following the manufacturer's instructions. Deep sequencing using Hiseq4000 with paired-end (75 bp) runs was performed by the Wellcome Trust Centre for Human Genetics (WTCHG), Oxford, UK.

Real time PCR analyses {#s4-14}
----------------------

ChrRNA was extracted from synchronised HeLa cells 48 hr after siRNA transfection as described above. For reverse transcription, 500 to 900 ng of ChrRNA from each sample was used to generate single-strand cDNA by incubation with random hexamers (*Qiagen*) and Superscript III reverse transcriptase (*Life Technologies*). Quantitative RT-PCR was performed using the SYBR Green Master Mix (*Qiagen*). Relative RNA levels were calculated using the ΔCt method. Data were acquired and analysed using Rotor-GeneQ (*Qiagen*). Defects in 3ʹ end transcription termination were evaluated using amplicons located downstream of the 3ʹ untranslated region (3ʹ UTR) of RD histone genes. The relative abundance of unprocessed sequences was normalised to the relative abundance of an amplicon covering a portion of the GAPDH gene body (GB) or to the corresponding histone GB abundance. Primers used are listed in [Table 2](#table2){ref-type="table"}. Similarly, chrRNA was extracted from synchronised wild-type and CRISPR/Cas9-mediated MBLAC1-depleted HeLa cells; cDNA libraries and quantitative RT-PCR were performed as above.

Chromatin RNA-Seq data processing {#s4-15}
---------------------------------

GRCh38 was used as a reference genome. RNA-sequencing reads were trimmed using Cutadapt 1.8.3 ([@bib37]). An in-house Perl scripts Perl script was used to remove the reads left unpaired. The remaining reads were then aligned to the human reference genome with Tophat 2.0.13 ([@bib58]; [@bib59]) using parameters: tophat -g 1 r 3000 \--no-coverage-search. Aligned reads were processed to only include properly paired, properly mapped reads with no more than two mismatches using SAMtools 1.2 ([@bib35]). Data were scaled to library size (genomeCoverageBed) using Bedtools ([@bib46]). For data vizualization, trackhubs for the UCSC browser were created by employing the UCSC bedGraphToBigWig tool ([@bib29]). For the gene body normalised plots, expression levels (as reads per kilobase per million mapped reads, RPKMs) were calculated for a region of \'TES-100bp\' for each gene in all the three samples, namely, LUC, MBLAC1 and CPSF73. These values were then used to normalise each base position followed by plotting them using Python script. Gene body normalised plots were then log two transformed.

RNA-chromatin immunoprecipitation analysis {#s4-16}
------------------------------------------

Wild-type and MBLAC1 C-terminal FLAG knock in HeLa cells were synchronised in early S-phase using a double thymidine block and used in RNA-chromatin immunoprecipitation (RNA-ChIP) experiments as described by B. K. Sun and J. T. Lee ([@bib59]). An additional TURBO DNase (*Ambion*) treatment was repeated at the end of the procedure to ensure complete chromatin digestion. The obtained immunoprecipitated RNA was used to prepare cDNA libraries and quantitative RT-PCR was performed as above. RNA levels were calculated using the standard curve method. Data were acquired and analysed using Rotor-GeneQ (*Qiagen*). Primer sets used in the experiments are listed in [Table 2](#table2){ref-type="table"}.

CRISPR/Cas9-mediated MBLAC1 deletion {#s4-17}
------------------------------------

Single guide RNA (sgRNA) constructs aiming to delete the MBLAC1 gene in HeLa cells were designed and produced by the Genome Engineering Oxford Facility, Oxford University, UK ([Table 2](#table2){ref-type="table"}). HeLa cells were transiently co-transfected with two sgRNA constructs (vector epX459(1.1)), both carrying the engineered hSpCas9(1.1) gene ([@bib55]) and a sgRNA cassette targeting the 5ʹ or 3ʹ region flanking the MBLAC1 gene using Fugene HD transfection reagent (*Promega*), following the manufacturer's instructions. 24 hr after transfection, cells were exposed to puromycin (2 µg/ml) for 24 hr to positively select transfected cells. After recovery, cells were harvested and used to select MBLAC1-depleted cell clones by limiting dilution plating and to isolate genomic DNA to evaluate the gene deletion efficiency by PCR ([Table 2](#table2){ref-type="table"}). Genomic DNA was then extracted from cell clones and PCR reactions amplifying the DNA region flanking the sgRNA targeting sites were performed to confirm MBLAC1 gene deletion. PCR products corresponding to the wt gene or to the gene deletion were gel purified and their sequence confirmed by Sanger sequencing. Total RNA was then extracted from cell clones carrying the MBLAC1 deletion using TRI reagent (*Ambion*) following the manufacturer's instructions. RT-qPCR analyses were performed to evaluate MBLAC1 mRNA levels after CRISPR/Cas9-mediated depletion as above. RT-qPCR products were analysed by Sanger sequencing.

CRISPR/Cas9-mediated MBLAC1 C-terminal FLAG knock in generation {#s4-18}
---------------------------------------------------------------

HeLa cells were transiently co-transfected with a single guide RNA (sgRNA) construct targeting the 3ʹ region flanking the MBLAC1 gene (previously used to delete the MBLAC1 gene in HeLa cells) and with a pUC19 vector (*NEB*) carrying a FLAG tag sequence flanked at both 5\' and 3\' by \~300 nucleotides sequence corresponding to the genomic sequence flanking the 3\' region of the MBLAC1 gene using Fugene HD transfection reagent (*Promega*), following the manufacturer's instructions. Similarly to the CRISPR/Cas9-mediated MBLAC1 deletion, 24 hr after transfection, cells were exposed to puromycin (2 µg/ml) for 24 hr to positively select transfected cells. After recovery, cells were harvested and used to select MBLAC1 knock in (Kin) cell clones by limiting dilution plating and to isolate genomic DNA to evaluate the FLAG sequence insertion efficiency by PCR ([Table 2](#table2){ref-type="table"}). Positive cells clones were growth as usual and analysed by western blot to validate the FLAG tag insertion at protein level using an anti-FLAG antibody.

Polyadenylated RNA selection {#s4-19}
----------------------------

Total RNA was extracted from wild-type and CRISPR/Cas9-mediated MBLAC1-depleted HeLa cells after synchronization in early S-phase using the TRI reagent (*Ambion*). The Dynabeads mRNA purification kit (*Ambion*) was used to positively select polyadenylated RNA following the manufacturer's instructions; unbound RNA was considered as the unpolyadenylated RNA fraction. Both RNA fractions were phenol-chloroform extracted and ethanol precipitated, then solubilized in 20 µL ddH~2~O. For reverse transcription, 1 µg of total, polyadenylated and unpolyadenylated RNA from each sample was used to generate single-strand cDNA by incubation with random hexamers (*Qiagen*) and Superscript III reverse transcriptase (*Life Technologies*). Quantitative RT-PCR was performed using the SYBR Green Master Mix (*Qiagen*). RNA levels were calculated using the standard curve method. Data were acquired and analysed using Rotor-GeneQ (*Qiagen*). Primer sets used in the experiments are listed in [Table 2](#table2){ref-type="table"}).

Data analysis and statistics {#s4-20}
----------------------------

The number of biological repeats and statistical tests (conducted in Microsoft Excel or GraphPad) are indicated in the corresponding figure legends. Error bars representing s.e.m. are shown where appropriate.
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"Biosynthesis of histone messenger RNA employs a specific 3\' end endonuclease\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, and the evaluation has been overseen by a Reviewing Editor and James Manley as the Senior Editor. The reviewers have opted to remain anonymous.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission. Given the significance of the points raised, the paper will need to be seen again by the reviewers.

The paper by Schofield, Proudfoot, and colleagues characterizes the MBLAC1 protein. The authors obtain a crystal structure of the protein, which suggests that MBLAC1 could function as an RNase. Biochemical assays provide largely convincing evidence that MBLAC1 indeed possesses endonuclease activity and has a preference for CA sequence. To investigate its in vivo function, the authors knock down MBLAC1 and observe cell cycle and transcription termination defects, which are suggested to be specific for replication-dependent (RD) histone genes.

Overall the structural and biochemical data convincingly show that MBLAC1 can function as an RNA endonuclease. However, the reviewers are not fully convinced that MBLAC1 is specifically involved in RD histone RNA 3\' end processing and suggest additional analyses to examine this key question.

Essential revisions:

1\) The meta-gene analyses show overall higher expression levels for histone genes both upstream and downstream of the transcript end site (TES) (Figure 4D). Hence, the read-through signal appears much less significant than what is stated. This is unusual for a termination factor. Could the higher signals downstream of the TES simply be an indirect effect of higher histone mRNA expression or is this a normalization issue? If the latter, this data should be presented as gene-body normalized and/or as heat maps illustrating all individual histone mRNAs. Also, the genome browser images (e.g. Figure 4B-C) do not fully convey how the gene-body vs read-through signal relate to one another.

2\) RD histone RNA 3\'end processing has been extensively studied and the machinery is well characterized. The authors fail to provide strong evidence linking MBLAC1 to known RD histone RNA 3\'end processing factors. They cite that MBLAC1 binds to Clp1, but it is not clear that Clp1 functions in RD histone RNA processing. Is it possible that MBLAC1 might participate independent of other known factors? To demonstrate this, the authors need to provide evidence that MBLAC1 at least associates with histone gene TESs, for example by ChIP assays.

3\) Figure 1, Figure 5 and Figure 6: The authors should show the purity of the purified proteins on silver-stained SDS gels. In order to completely exclude contaminating nuclease activity, results in Figure 5 and Figure 6 could be complemented with catalytically dead protein purified from HEK293 cells.

4\) Figure 3, Figure 4, Figure 4---figure supplement 1, Figure 4---figure supplement 2: How is it possible that histone H3 protein levels are down upon MBLAC1 depletion (either by siRNA or CRISPR), when the corresponding mature mRNA levels appear either unaffected or increased?

5\) The data presented in the paper doesn\'t convincingly show that MBLAC1 is selective for RD histone transcripts: In Figure 4B/ Figure 4---figure supplement 2A, there are more reads immediately downstream of the TES in siMBLAC1 than in the siLuc control. Could there also be a defect in processing of polyadenylated transcripts? It would be helpful to show a metagene analysis for canonical mRNAs (as in Figure 4D).

\[Editors\' note: further revisions were requested prior to acceptance, as described below.\]

Thank you for resubmitting your work entitled \"Biosynthesis of histone messenger RNA employs a specific 3\' end endonuclease\" for further consideration at *eLife*. Your revised article has been favorably evaluated by James Manley (Senior Editor) and a Reviewing Editor.

The manuscript has been improved but there are some remaining issues that need to be addressed before acceptance, as outlined below:

1\) Insufficient labeling of figures is a source of confusion and should be improved.

2\) The CLP1 co-IP still appears misplaced. Consider removing it entirely.

3\) Figure 4---figure supplement 3: In the interest of clarity, how about plotting the three tracks (siLuc, siCPSF73, siMBLAC1) in the same graph? Try a log2-transformation of the data to make the read-through region stand out more clearly?

4\) Discussion section: "\[...\] recognition of the secondary structure of the stem-loop by MBLAC1 is important in maintaining the specificity of the cleavage" Why recognition? Is it not more likely that the structure prevents MBLAC1 to access the putative single-stranded cleavage sites?

5\) The MBLAC1 RNA-ChIP experiment is not convincing. At a very minimum the authors should include an input sample to assay RDH expression relative to GAPDH and to confirm that RDH expression is not affected by the tagging of MBLAC1.

\[Editors\' note: further revisions were requested prior to acceptance, as described below.\]

Thank you for resubmitting your work entitled \"Biosynthesis of histone messenger RNA employs a specific 3\' end endonuclease\" for further consideration at eLife. Your revised article has been favorably evaluated by a Reviewing Editor and a Senior Editor.

The manuscript has been improved but there are some remaining issues that need to be addressed before acceptance, as outlined below:

The authors have addressed most of the concerns appropriately. However, one concern remains regarding the generality of MBLAC1 in RD histone termination. This should be clarified both in the figures and in the text. Especially the RD histone tracks in Figure 4---figure supplement 3 are not convincing to state that MBLAC1 is generally involved in this process.

Specific comments concerning Figure 4---figure supplement 3:

1\) The interpretation of the shown plots is left as an exercise to the reader. To resolve this, 2 modifications can be suggested: 1) Indicate clearly in each plot the genomic region where an increased read-through upon knock-down of MBLAC1 and/or CPSF73 is observed, and 2) Sort or group plots into classes where read-through is observed, not observed or ambiguous. Once, this is done, please modify the text accordingly (it looks like only a subset of RD histone genes display read-through upon MBLAC1 knock-down).

2\) The claimed gene-body normalization in panel A is not apparent from the shown data. Why?

3\) The figure legend claims that regions (TSS-100 bp, TES+200 bp in panel A) and (TSS-200 bp, TES +200 bp in panel B) are depicted. Neither appears to reflect what is shown. Is it regions TES-100 to TES+200?

4\) Are the data showing the average of the 2 replicates or something else? This is not clarified.

5\) Why should log2 transformation not be compatible with gene-body normalization of the data?

10.7554/eLife.39865.025

Author response

> Essential revisions:
>
> 1\) The meta-gene analyses show overall higher expression levels for histone genes both upstream and downstream of the transcript end site (TES) (Figure 4D). Hence, the read-through signal appears much less significant than what is stated. This is unusual for a termination factor. Could the higher signals downstream of the TES simply be an indirect effect of higher histone mRNA expression or is this a normalization issue? If the latter, this data should be presented as gene-body normalized and/or as heat maps illustrating all individual histone mRNAs. Also, the genome browser images (e.g. Figure 4B-C) do not fully convey how the gene-body vs read-through signal relate to one another.

We thank the reviewer for these very helpful comments and suggestions. We understand the concern about the meta-gene analyses. Unfortunately, the higher histone gene expression level observed in the control sample (siLUC) leads to a normalization issue in comparing the extent of read through with the knock downs when the data were scaled to library size (which is a standard method for meta-gene analyses). To avoid the normalization issue the raw data were plotted for individual histone genes (Figure 4---figure supplement 3) showing in more detail the different histone genes that are affected by MBLAC1 or CPSF73 knock down. This approach enables better comparison with the results of other experiments where the relative abundance of unprocessed RNA was normalized not only to the abundance of a house-keeping gene (GAPDH), but also to that of the corresponding histone gene-body (as suggested by the reviewer). The results from the two methods are consistent (Figure 4D,E). We believe that the revaluation of these data will reassure the reviewer regarding the authentic effect of MBLAC1 on histone pre-mRNA.

> 2\) RD histone RNA 3\'end processing has been extensively studied and the machinery is well characterized. The authors fail to provide strong evidence linking MBLAC1 to known RD histone RNA 3\'end processing factors. They cite that MBLAC1 binds to Clp1, but it is not clear that Clp1 functions in RD histone RNA processing. Is it possible that MBLAC1 might participate independent of other known factors? To demonstrate this, the authors need to provide evidence that MBLAC1 at least associates with histone gene TESs, for example by ChIP assays.

We thank the reviewer for these comments and suggestions for helpful new experiments, which we have carried out. We agree with the reviewer's suggestion that MBLAC1 may well act independently from other known histone pre-mRNA processing factors, as we suggest in the manuscript and as supported by the observation MBLAC1 manifests substrate specificity in its purified form (see Figure 5 and Figure 6). We have carried out ChIP analyses to investigate the potential association of MBLAC1 with histone genes. Unfortunately, although our results pointed in this direction, the background signal was too high to allow definitive analyses. We therefore focused our efforts on RNA-Chromatin immunoprecipitation analyses. In both cases (ChIP and RNA-ChIP experiments) we used a C-terminal FLAG tagged MBLAC1 cell line generated from HeLa cells using CRISPR/Cas9 technology. This enabled us to use an anti-FLAG antibody to immunoprecipitate MBLAC1 at endogenous levels (anti-MBLAC1 antibodies suitable for IP are not currently commercially available). As shown in Figure 4G the comparison of controls (from both WT HeLa cells and FLAG cell line) and anti-FLAG samples (from FLAG tagged MBLAC1 knock in cells) clearly shows that the observed RIP signal for histone mRNA is not due to background but is MBLAC1 specific. This proposal is also supported by comparison of the signal detected for RD histones and normal protein coding mRNA (GAPDH) obtained after immunoprecipitation of MBLAC1 or FLASH. As shown, both anti-FLAG and anti-FLASH samples result in very similar RNA-ChIP profiles. We used FLASH as internal control because it is a well-known member of the 3′ histone pre-mRNA machinery (Marzluff, 2017). Even though the resolution limit of the technique cannot clearly distinguish between the TSS and TES of the histone mRNA due to the small size of these transcripts, the similar enrichments shown by both anti-FLAG and anti-FLASH are reassuring.

> 3\) Figure 1, Figure 5 and Figure 6: The authors should show the purity of the purified proteins on silver-stained SDS gels. In order to completely exclude contaminating nuclease activity, results in Figure 5 and Figure 6 could be complemented with catalytically dead protein purified from HEK293 cells.

Following the reviewer's suggestion, we now show protein purity by silver-stained SDS gel using wild-type and active site variant (mutMBLAC1) produced in both *E. coli* and HEK293 cells (Figure 5A). As shown, all the preparations are \>95% pure (by gel analysis) except for the mutant enzyme produced in HEK293 cells. The somewhat lower HEK293 mutant (mutMBLAC1) enzyme purity implies a lack of contaminating nucleases: the observation mutMBLAC1 is less pure and less active is supportive of a lack of contaminating nucleases in our preparations (Figure 5A). The results shown in the previous versions of Figure 5 and Figure 6 have been complemented with new results (Figure 5D and Figure 6B); notably, analogous wild-type and active site variant (mutMBLAC1) proteins produced in HEK293 cells show similar catalytic properties to those produced in bacteria.

> 4\) Figure 3, Figure 4, Figure 4---figure supplement 1, Figure 4---figure supplement 2 : How is it possible that histone H3 protein levels are down upon MBLAC1 depletion (either by siRNA or CRISPR), when the corresponding mature mRNA levels appear either unaffected or increased?

We thank the reviewer for the comment. These observations can be explained either by a compensating effect (low protein levels stimulate higher transcription or increased RNA stability) (Radhakrishnan, 2016), or by the increased stability and nuclear retention of unproperly terminated (possibly polyadenylated) RD histone pre-mRNA following incorrect 3′ end cleavage (Romeo, 2014). Either way, when the reviewer refers to "mature mRNA levels", we believe that these transcripts should be considered as the totality of both properly and improperly processed histone pre-mRNA (this is because not all the improperly processed pre-mRNA appear to undergo polyadenylation).

> 5\) The data presented in the paper doesn\'t convincingly show that MBLAC1 is selective for RD histone transcripts: In Figure 4B/ Figure 4---figure supplement 2A, there are more reads immediately downstream of the TES in siMBLAC1 than in the siLuc control. Could there also be a defect in processing of polyadenylated transcripts? It would be helpful to show a metagene analysis for canonical mRNAs (as in Figure 4D).

We thank the reviewer for this comment. In [Author response image 1](#respfig1){ref-type="fig"} we show the results of a meta-gene analysis, indicating that MBLAC1 depletion does not affect (within detection limits) canonical mRNAs.

![](elife-39865-resp-fig1){#respfig1}

\[Editors\' note: further revisions were requested prior to acceptance, as described below.\]

> The manuscript has been improved but there are some remaining issues that need to be addressed before acceptance, as outlined below:
>
> 1\) Insufficient labeling of figures is a source of confusion and should be improved.

We have worked to improve the labelling quality and the overall symmetry of each figure. We hope that now the figures appear also more consistent -- please let us know if anything else needs attention.

> 2\) The CLP1 co-IP still appears misplaced. Consider removing it entirely.

Following your suggestion, the CLP1 co-IP experiment has been removed. We understand the motivation for removing it and aim to carry out further investigations on the CLP1 interaction in the future.

> 3\) Figure 4---figure supplement 3: In the interest of clarity, how about plotting the three tracks (siLuc, siCPSF73, siMBLAC1) in the same graph? Try a log2-transformation of the data to make the read-through region stand out more clearly?

Thank you for this suggestion. The expression levels of RD histone genes in the control sample (siLuc) are higher compared to those in both the MBLAC1 and CPSF73 depletions rendering the log2-transformation inappropriate for clear presentation. Thus, to address the issue, we have used gene-body normalization as follows: expression levels (as reads per kilobase per million mapped reads, RPKMs) were calculated for a region of \'TES-100bp\' for each of the analysed histone genes in all the samples (siLUC, siMBLAC1, and siCPSF73). These values were then used to normalize each base position. For clarity, we have presented the data in both ways, i.e. (A) Gene-body normalization for each analysed histone gene and (B) Raw data plotted for individual histone genes (previous Figure 4---figure supplement 3).

> 4\) Discussion section: "\[...\] recognition of the secondary structure of the stem-loop by MBLAC1 is important in maintaining the specificity of the cleavage" Why recognition? Is it not more likely that the structure prevents MBLAC1 to access the putative single-stranded cleavage sites?

We thank the editors for this useful comment. We have modified the text in agreement with the suggestion as follows: "The degradation patterns observed for RNA 4 and 5 suggest that the stem-loop substrate structure prevents MBLAC1 from accessing putative single-stranded cleavage sites located upstream of position 27, thus helping to maintain specificity of cleavage at position 27."

> 5\) The MBLAC1 RNA-ChIP experiment is not convincing. At a very minimum the authors should include an input sample to assay RDH expression relative to GAPDH and to confirm that RDH expression is not affected by the tagging of MBLAC1.

Following the suggestion, we have modified Figure 4 with a new graphical representation (Figure 4G) of the relative abundance of RD histone mRNA in both samples (wild-type and MBLAC1 FLAG knock in inputs). The relative abundance has been normalized to the abundance of GAPDH mRNA in the corresponding sample. The observed results are consistent with the RD histone mRNA level not being affected by the tagging of MBLAC1.

\[Editors\' note: further revisions were requested prior to acceptance, as described below.\]

> 1\) The interpretation of the shown plots is left as an exercise to the reader. To resolve this, 2 modifications can be suggested: 1) Indicate clearly in each plot the genomic region where an increased read-through upon knock-down of MBLAC1 and/or CPSF73 is observed, and 2) Sort or group plots into classes where read-through is observed, not observed or ambiguous. Once, this is done, please modify the text accordingly (it looks like only a subset of RD histone genes display read-through upon MBLAC1 knock-down).

We grouped the plots as you suggested based on the read-through effect (into major, possible, and not observed) and have colour-highlighted the genomic region where an increased read-through upon knock-down of MBLAC1 and/or CPSF73 was observed in each plot. We have also modified the main text (subsection "MBLAC1 is involved in histone-specific pre-mRNA processing in vivo") and the figure accordingly.

> 2\) The claimed gene-body normalization in panel A is not apparent from the shown data. Why?

See response to point 5 please.

> 3\) The figure legend claims that regions (TSS-100 bp, TES+200 bp in panel A) and (TSS-200 bp, TES +200 bp in panel B) are depicted. Neither appears to reflect what is shown. Is it regions TES-100 to TES+200?

Thank you and apologies for the typo 'TSS' in the figure legend that now has been corrected to TES and the +/- from TES has been adjusted based on the now modified Figure 4*---*figure supplement 3.

> 4\) Are the data showing the average of the 2 replicates or something else? This is not clarified.

The data represents the average of the 2 biological replicates. We are sorry for the lack of clarity. We have modified the text to make this clear.

> 5\) Why should log2 transformation not be compatible with gene-body normalization of the data?

In the now modified Figure 4*---*figure supplement 3 the gene-body normalized data have been log 2 transformed to make the read-through region stand out more clearly -- thank you for this suggestion. (The log 2 transformation was not applied to the previous version of the figure and this is probably the reason why the gene-body normalization was less appreciable in the previous version of the figure).
